Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue Beat Signals Near-Term Commercial Momentum

Solid top-line delivery and a strong cash position support a constructive near-term commercial backdrop despite continued operating losses.

Recent News

Nov 3, 2025 — Investors Business Daily reported Agios cleared a technical RS threshold, lifting its RS Rating to 81 and noting recent sales growth; Oct 30, 2025 — multiple outlets covered Agios’ scheduled Q3 2025 results release and related investor materials (company webcast announced Oct 16).

Technical Analysis

ADX stands at 22.3, indicating an emerging trend strength; coupled with the directional indicators, trend strength now matters for short-term direction.

DI+ at 25.9 shows a peak-and-reversal, which signals bearish directional pressure; DI- at 19.68 shows a dip-and-reversal, reinforcing bearish directional pressure.

MACD sits at 0.81 below its 0.99 signal and displays a peak-and-reversal, indicating bearish momentum in the oscillator despite a positive absolute MACD value.

MRO reads -6.2, which places price below the WMDST target and implies upside potential from a valuation gap; the MRO trend shows a peak-and-reversal, reducing near-term upside momentum.

RSI at 55.47 with a peak-and-reversal shows the oscillator backing away from recent strength while remaining in neutral territory — short-term momentum weakened without oversold conditions.

Price trades at $40.13, below the 20-day average ($42.39) and under the 1x Bollinger lower band ($41.29), indicating short-term weakness versus recent volatility; price remains above the 200-day average ($34.72), which supports a longer-term recovery context.

Short-term EMAs show pressure: the 12-day EMA at $42.16 carries a peak-and-reversal, and the 26-day EMA at $41.39 sits above the close, signaling near-term bearish bias against longer-term averages.

Ichimoku components place the cloud (Senkou A/B: $36.93 / $34.24) below current price, which provides structural support beneath current levels; the Kijun at $40.32 sits near the close and can act as a short-term reference.

Volume at 834,696 exceeds the 10-day average (573,486) and the 50/200-day averages, suggesting recent directional moves carried meaningful participation and that short-term directional signals warrant attention.

 


Fundamental Analysis

Total revenue registers $12,455,000 for the period; YoY revenue growth equals 721.49% while the reported revenue growth metric shows 42.73% (both values provided). Product sales growth underpins the beat versus consensus reported alongside the quarter.

EPS came in at -$1.78 versus an estimate of -$1.90, a positive surprise of $0.12 or +6.32% versus estimates; the narrower-than-expected loss reflects revenue upside and controlled non‑recurring items.

Operating performance remains loss-making: EBIT stands at -$127,056,000 and EBIT margin at -10.20%. The EBIT margin sits below the industry peer mean of -0.73% and below the industry peer median of 0.24%, indicating profitability lags typical peer margins despite progress on revenue.

Liquidity and balance-sheet strength stand out: cash and short-term investments total $938,937,000 and cash alone $80,871,000; current ratio 14.48 and quick ratio 14.04 signal ample near-term coverage of liabilities.

Leverage stays low: total debt $48,760,000 with debt-to-assets at 3.31% and debt-to-equity at 3.56%, well inside the industry peer range and consistent with a conservative capital structure.

Cash flow dynamics show operating cash flow of -$77,124,000 and free cash flow of -$87,999,000, yielding a free cash flow yield of -4.18%; free cash flow remains negative as investment and commercialization ramping continue.

Gross margin at 86.34% outperforms the industry peer mean, supporting strong product-level economics on existing revenue streams.

Key growth and efficiency metrics: receivables turnover 2.99 and asset turnover very low at 0.82% (asset turnover sits well below the industry peer mean of 11.54%), reflecting a commercial-stage company with concentrated product revenue and large asset base.

Earnings growth shows positive momentum numerically (earnings growth +24.52% and QoQ strength), but absolute profitability remains negative and influenced by R&D and SG&A investments for pipeline expansion.

Valuation context: price-to-book at 1.54 sits below the industry peer mean of 5.29; price-to-sales at 169.18 stands above the industry peer mean of 56.00, reflecting low revenue base versus market capitalization. WMDST values the stock as under-valued.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-06-30
REPORT DATE: 2025-10-30
NEXT REPORT DATE: 2026-01-29
CASH FLOW  Begin Period Cash Flow 79.0 M
 Operating Cash Flow -77.12 M
 Capital Expenditures -10.88 M
 Change In Working Capital 8.3 M
 Dividends Paid
 Cash Flow Delta 1.9 M
 End Period Cash Flow 80.9 M
 
INCOME STATEMENT REVENUE
 Total Revenue 12.5 M
 Forward Revenue 2.5 M
COSTS
 Cost Of Revenue 1.7 M
 Depreciation 1.3 M
 Depreciation and Amortization 1.3 M
 Research and Development 91.9 M
 Total Operating Expenses 139.5 M
PROFITABILITY
 Gross Profit 10.8 M
 EBITDA -125.80 M
 EBIT -127.06 M
 Operating Income -127.06 M
 Interest Income 14.5 M
 Interest Expense
 Net Interest Income 14.5 M
 Income Before Tax -112.02 M
 Tax Provision
 Tax Rate
 Net Income -112.02 M
 Net Income From Continuing Operations -112.02 M
EARNINGS
 EPS Estimate -1.90
 EPS Actual -1.78
 EPS Difference 0.12
 EPS Surprise 6.316 %
 Forward EPS -1.52
 
BALANCE SHEET ASSETS
 Total Assets 1.5 B
 Intangible Assets
 Net Tangible Assets 1.4 B
 Total Current Assets 1.0 B
 Cash and Short-Term Investments 938.9 M
 Cash 80.9 M
 Net Receivables 5.0 M
 Inventory 30.8 M
 Long-Term Investments 3.9 M
LIABILITIES
 Accounts Payable 17.5 M
 Short-Term Debt
 Total Current Liabilities 70.4 M
 Net Debt
 Total Debt 48.8 M
 Total Liabilities 101.7 M
EQUITY
 Total Equity 1.4 B
 Retained Earnings -350.23 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 23.60
 Shares Outstanding 58.039 M
 Revenue Per-Share 0.21
VALUATION
 Market Capitalization 2.1 B
 Enterprise Value 1.2 B
 Enterprise Multiple -9.674
Enterprise Multiple QoQ 5.127 %
Enterprise Multiple YoY -45.507 %
Enterprise Multiple IPRWA high: 47.216
median: 14.143
mean: 5.461
AGIO: -9.674
low: -68.907
 EV/R 97.707
CAPITAL STRUCTURE
 Asset To Equity 1.074
 Asset To Liability 14.469
 Debt To Capital 0.034
 Debt To Assets 0.033
Debt To Assets QoQ -2.615 %
Debt To Assets YoY -19.23 %
Debt To Assets IPRWA high: 0.995
mean: 0.187
median: 0.062
AGIO: 0.033
low: 0.0
 Debt To Equity 0.036
Debt To Equity QoQ -1.385 %
Debt To Equity YoY -25.864 %
Debt To Equity IPRWA high: 1.706
mean: 0.25
median: 0.059
AGIO: 0.036
low: -1.039
PRICE-BASED VALUATION
 Price To Book (P/B) 1.539
Price To Book QoQ 24.667 %
Price To Book YoY -57.452 %
Price To Book IPRWA high: 16.592
median: 6.295
mean: 5.286
AGIO: 1.539
low: -10.064
 Price To Earnings (P/E) -18.266
Price To Earnings QoQ -9.445 %
Price To Earnings YoY -26.49 %
Price To Earnings IPRWA high: 44.732
mean: -11.199
median: -13.453
AGIO: -18.266
low: -73.374
 PE/G Ratio -0.745
 Price To Sales (P/S) 169.179
Price To Sales QoQ -18.434 %
Price To Sales YoY -38.977 %
Price To Sales IPRWA high: 517.227
AGIO: 169.179
mean: 56.005
median: 19.711
low: 0.25
FORWARD MULTIPLES
Forward P/E -21.116
Forward PE/G -0.861
Forward P/S 859.293
EFFICIENCY OPERATIONAL
 Operating Leverage 0.448
ASSET & SALES
 Asset Turnover Ratio 0.008
Asset Turnover Ratio QoQ 51.845 %
Asset Turnover Ratio YoY -22.505 %
Asset Turnover Ratio IPRWA high: 0.388
mean: 0.115
median: 0.113
AGIO: 0.008
low: -0.001
 Receivables Turnover 2.99
Receivables Turnover Ratio QoQ 27.707 %
Receivables Turnover Ratio YoY 25.222 %
Receivables Turnover Ratio IPRWA high: 6.517
AGIO: 2.99
median: 1.422
mean: 1.405
low: 0.012
 Inventory Turnover 0.056
Inventory Turnover Ratio QoQ 48.497 %
Inventory Turnover Ratio YoY -11.476 %
Inventory Turnover Ratio IPRWA high: 2.946
mean: 0.607
median: 0.434
AGIO: 0.056
low: 0.006
 Days Sales Outstanding (DSO) 30.514
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 1258.184
Cash Conversion Cycle Days QoQ 24.414 %
Cash Conversion Cycle Days YoY -34.362 %
Cash Conversion Cycle Days IPRWA AGIO: 1258.184
high: 1140.813
median: 205.05
mean: 199.777
low: -1350.846
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.013
 CapEx To Revenue -0.873
 CapEx To Depreciation -8.638
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 1.4 B
 Net Invested Capital 1.4 B
 Invested Capital 1.4 B
 Net Tangible Assets 1.4 B
 Net Working Capital 949.1 M
LIQUIDITY
 Cash Ratio 13.335
 Current Ratio 14.479
Current Ratio QoQ -21.723 %
Current Ratio YoY 43.471 %
Current Ratio IPRWA high: 25.128
AGIO: 14.479
mean: 3.916
median: 2.52
low: 0.021
 Quick Ratio 14.041
Quick Ratio QoQ -21.698 %
Quick Ratio YoY 44.606 %
Quick Ratio IPRWA AGIO: 14.041
high: 10.544
mean: 2.948
median: 2.158
low: 0.021
COVERAGE & LEVERAGE
 Debt To EBITDA -0.388
 Cost Of Debt 0.018 %
 Interest Coverage Ratio -12705.6
Interest Coverage Ratio QoQ 19.157 %
Interest Coverage Ratio YoY 20.071 %
Interest Coverage Ratio IPRWA high: 940.414
mean: 45.392
median: 2.742
low: -1465.352
AGIO: -12705.6
 Operating Cash Flow Ratio -1.56
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 1314.421
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate -5.418 %
 Revenue Growth 42.734 %
Revenue Growth QoQ -328.805 %
Revenue Growth YoY 721.492 %
Revenue Growth IPRWA high: 269.352 %
AGIO: 42.734 %
mean: 20.376 %
median: 12.272 %
low: -259.856 %
 Earnings Growth 24.516 %
Earnings Growth QoQ 220.932 %
Earnings Growth YoY 48.115 %
Earnings Growth IPRWA high: 155.0 %
AGIO: 24.516 %
median: 11.33 %
mean: 2.353 %
low: -181.25 %
MARGINS
 Gross Margin 86.335 %
Gross Margin QoQ -1.406 %
Gross Margin YoY 4.462 %
Gross Margin IPRWA high: 100.0 %
AGIO: 86.335 %
median: 80.103 %
mean: 77.812 %
low: -77.751 %
 EBIT Margin -1020.12 %
EBIT Margin QoQ -16.518 %
EBIT Margin YoY -16.948 %
EBIT Margin IPRWA high: 338.783 %
median: 23.755 %
mean: -73.27 %
AGIO: -1020.12 %
low: -5123.44 %
 Return On Sales (ROS) -1020.12 %
Return On Sales QoQ -16.518 %
Return On Sales YoY -16.948 %
Return On Sales IPRWA high: 89.247 %
median: 28.85 %
mean: -77.093 %
AGIO: -1020.12 %
low: -5698.0 %
CASH FLOW
 Free Cash Flow (FCF) -88.00 M
 Free Cash Flow Yield -4.176 %
Free Cash Flow Yield QoQ -32.667 %
Free Cash Flow Yield YoY 37.098 %
Free Cash Flow Yield IPRWA high: 36.371 %
median: 0.516 %
mean: -0.332 %
AGIO: -4.176 %
low: -74.318 %
 Free Cash Growth -21.608 %
Free Cash Growth QoQ 32.475 %
Free Cash Growth YoY -20.731 %
Free Cash Growth IPRWA high: 157.51 %
median: 13.562 %
mean: 3.883 %
AGIO: -21.608 %
low: -183.577 %
 Free Cash To Net Income 0.786
 Cash Flow Margin -881.895 %
 Cash Flow To Earnings 0.981
VALUE & RETURNS
 Economic Value Added
 Return On Assets (ROA) -7.402 %
Return On Assets QoQ 33.417 %
Return On Assets YoY -37.515 %
Return On Assets IPRWA high: 36.544 %
median: 1.616 %
mean: -1.385 %
AGIO: -7.402 %
low: -68.545 %
 Return On Capital Employed (ROCE) -9.07 %
 Return On Equity (ROE) -0.082
Return On Equity QoQ 34.346 %
Return On Equity YoY -43.795 %
Return On Equity IPRWA high: 1.117
median: 0.04
mean: 0.008
AGIO: -0.082
low: -1.572
 DuPont ROE -7.9 %
 Return On Invested Capital (ROIC)
Return On Invested Capital QoQ
Return On Invested Capital YoY
Return On Invested Capital IPRWA

Six-Week Outlook

Near-term price action likely stays dictated by execution headlines and short-term technical momentum. The combination of an emerging ADX, bearish DI+/DI- shifts, MACD below its signal, and price beneath short-term EMAs suggests a period of consolidation with downside pressure testing structural supports. Robust cash and above‑average gross margins provide a fundamental buffer that favors stabilization above longer-term averages provided clinical and commercial progress continues to show positive headlines. For swing timeframes, monitor directional confirmation from the MACD and DI readings and any company announcements that materially alter revenue or cash‑flow expectations; those items will govern directional sustainability over the next six weeks.

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a trailblazing biopharmaceutical firm based in Cambridge, Massachusetts, dedicated to revolutionizing the treatment landscape for patients with rare and genetically defined diseases. Founded in 2007, Agios has carved a niche in the field of cellular metabolism, focusing on the development of pioneering therapies that address critical unmet medical needs. At the heart of Agios’ innovative portfolio is PYRUKYND (mitapivat), a groundbreaking activator of pyruvate kinase enzymes, offering hope to individuals suffering from hemolytic anemias. The company is also making strides with AG-946, targeting lower-risk myelodysplastic syndrome and hemolytic anemias, and AG-181, which aims to stabilize phenylalanine hydroxylase for the management of phenylketonuria. Agios’ commitment to scientific excellence extends to its preclinical pipeline, where it is exploring siRNA technology for the treatment of polycythemia vera, a rare and challenging blood disorder. Driven by a patient-centric ethos and a relentless pursuit of innovation, Agios Pharmaceuticals is poised to deliver transformative therapies that improve the lives of patients worldwide, setting new standards in the realm of metabolic disease treatment.



© 2025 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.